{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:44:49Z","timestamp":1793673889285,"version":"4.5.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AusperBio Therapeutics, Inc."},{"name":"Ausper Biopharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/purpose<\/jats:title>\n                    <jats:p>AHB-137 is a novel antisense oligonucleotide targeting a conserved 3\u2019-terminal region of HBV mRNA. This phase 1a\/1b study evaluated the safety, pharmacokinetics (PK), and antiviral activity of AHB-137 in Chinese healthy volunteers (HVs) and chronic hepatitis B (CHB) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In Phase 1a, 52 HVs received single ascending doses (75\u2013450\u00a0mg) or multiple ascending doses (MAD; 150 or 300\u00a0mg) of AHB-137 or placebo. In Phase 1b, 20 HBeAg-negative, nucleos(t)ide analogue (NA)-suppressed CHB patients with baseline HBsAg 100\u20131000\u00a0IU\/mL received MAD AHB-137 (150 or 300\u00a0mg) or placebo (8:2), and 2 patients with baseline HBsAg 1000\u20133000\u00a0IU\/mL received open-label AHB-137 300\u00a0mg. MAD comprised 6 subcutaneous doses over 4\u00a0weeks including loading doses on Days 4 and 11, with safety, PK and virologic follow-up assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No serious adverse events, deaths or discontinuations occurred. Most treatment-related adverse events were Grade 1\u20132, including injection site reactions, pyrexia, and asymptomatic lab abnormalities. Transaminase elevations were self-limiting; one Grade 3 ALT elevation in the 300\u00a0mg CHB cohort coincided with rapid HBsAg loss. PK showed rapid absorption (T\n                      <jats:sub>max<\/jats:sub>\n                      3\u20135\u00a0h), dose-proportionality, and a terminal half-life of 128\u2013195\u00a0h without meaningful accumulation. In CHB patients, 4\u00a0weeks of AHB-137 induced dose-dependent HBsAg reductions (mean maximum \u2212\u20091.1 vs. \u2212\u20092.1 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL at 150 vs. 300\u00a0mg), 50.0% of the 300\u00a0mg cohort achieved \u2265\u20092 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL reduction. Preliminary HBsAg loss was observed in a small subset of patients during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AHB-137 demonstrated favorable safety, predictable PK, and dose-dependent HBsAg reductions, including HBsAg loss, supporting its further development for CHB functional cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov. number: NCT06115993. Chinadrugtrials.org.cn. number: CTR20232098.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-026-11102-7","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:27:58Z","timestamp":1779535678000},"page":"1035-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety, pharmacokinetics and antiviral activity of AHB\u2011137 in healthy volunteers and chronic hepatitis B patients: a phase 1a\/1b study"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct06115993","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieer","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"4","key":"11102_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","volume":"83","author":"MG Ghany","year":"2026","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD\/IDSA practice guideline on treatment of chronic hepatitis B. Hepatology. 2026;83(4):974\u201397. https:\/\/doi.org\/10.1097\/HEP.0000000000001549","journal-title":"Hepatology"},{"issue":"10","key":"11102_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"Polaris Observatory Collaborators","year":"2023","unstructured":"Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of Hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879\u2013907","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"11102_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of Hepatitis B virus infection. J Hepatol. 2025;83(2):502\u2013583","journal-title":"J Hepatol"},{"key":"11102_CR4","volume":"51","author":"Z Hui","year":"2024","unstructured":"Hui Z, Yu W, Fuzhen W, Liping S, Guomin Z, Jianhua L, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac. 2024;51:101193","journal-title":"Lancet Reg Health West Pac"},{"issue":"17","key":"11102_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1097\/CM9.0000000000002331","volume":"135","author":"G Cao","year":"2022","unstructured":"Cao G, Liu J, Liu M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study. Chin Med J (Engl). 2022;135(17):2049\u20132055","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"11102_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","volume":"66","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296\u20131313","journal-title":"Hepatology"},{"issue":"8","key":"11102_CR7","first-page":"594","volume":"27","author":"Chinese Society of Infectious Disease Chinese Society of Hepatology CMA","year":"2019","unstructured":"Chinese Society of Infectious Disease Chinese Society of Hepatology CMA. The expert consensus on clinical cure (functional cure) of chronic hepatitis b. Zhonghua Gan Zang Bing Za Zhi. 2019;27(8):594\u2013603 (Chinese)","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"1","key":"11102_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jvh.13000","volume":"26","author":"HLY Chan","year":"2019","unstructured":"Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir\u2014a prospective study. J Viral Hepat. 2019;26(1):126\u2013135","journal-title":"J Viral Hepat"},{"issue":"5","key":"11102_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","volume":"13","author":"D Wu","year":"2019","unstructured":"Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13(5):573\u2013586","journal-title":"Hepatol Int"},{"issue":"21","key":"11102_CR10","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957\u20131968","journal-title":"N Engl J Med"},{"issue":"10","key":"11102_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"K Han","year":"2022","unstructured":"Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide Bepirovirsen in Hepatitis B virus-transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. Clin Pharmacol Drug Dev. 2022;11(10):1191\u20131202","journal-title":"Clin Pharmacol Drug Dev"},{"key":"11102_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)03293-2","volume":"78","author":"X Qiu","year":"2023","unstructured":"Qiu X, Lu T, Zhou H, Cao H, Zhang W, Chen G, et al. AHB-137, a novel and potent hepatitis B virus antisense oligonucleotide with a favorable preclinical pharmacokinetics and safety profile. J Hepatol. 2023;78: S1156","journal-title":"J Hepatol"},{"key":"11102_CR13","doi-asserted-by":"publisher","first-page":"S1152","DOI":"10.1016\/S0168-8278(23)03288-9","volume":"78","author":"X Wu","year":"2023","unstructured":"Wu X, Lu T, Zhang W, Bai Y, Zhang L, Ma S, et al. AHB-137, a novel hepatitis B virus antisense oligonucleotide with substantially enhanced in vitro and in vivo antiviral activity. J Hepatol. 2023;78:S1152\u2013S1153","journal-title":"J Hepatol"},{"key":"11102_CR14","unstructured":"National Cancer Institute. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited 2026 February 2]. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"11102_CR15","unstructured":"U.S. Food and Drug Administration. U.S. Food and Drug Administration. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials: Guidance for Industry. [cited 2026 February 2]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical."},{"issue":"4","key":"11102_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jhep.2022.08.020","volume":"77","author":"K Agarwal","year":"2022","unstructured":"Agarwal K, Lok J, Gane E. Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: opportunities and challenging the orthodoxy. J Hepatol. 2022;77(4):906\u2013908","journal-title":"J Hepatol"},{"issue":"6","key":"11102_CR17","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u20131442","journal-title":"J Clin Transl Hepatol"},{"issue":"17","key":"11102_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.21037\/atm-21-1666","volume":"9","author":"R Li","year":"2021","unstructured":"Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, et al. Cost-effectiveness of combination antiviral treatment with extended duration for Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med. 2021;9(17):1365","journal-title":"Ann Transl Med"},{"issue":"21","key":"11102_CR19","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.3748\/wjg.v21.i21.6684","volume":"21","author":"HM Li","year":"2015","unstructured":"Li HM, Wang JQ, Wang R, Zhao Q, Li L, Zhang JP. Hepatitis B virus genotypes and genome characteristics in China. World J Gastroenterol. 2015;21(21):6684\u20136697","journal-title":"World J Gastroenterol"},{"issue":"10","key":"11102_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","volume":"27","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide Bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021;27(10):1725\u20131734","journal-title":"Nat Med"},{"issue":"3","key":"11102_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jceh.2022.12.013","volume":"13","author":"A Kumar","year":"2023","unstructured":"Kumar A. Making sense of the antisense therapy for hepatitis B\u2014bepirovirsen. J Clin Exp Hepatol. 2023;13(3):535\u2013537","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"11102_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/nat.2016.0650","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, et al. The effects of 2\u2019-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 2017;27(3):121\u2013129","journal-title":"Nucleic Acid Ther"},{"issue":"2","key":"11102_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","volume":"82","author":"M Buti","year":"2025","unstructured":"Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82(2):222\u2013234","journal-title":"J Hepatol"},{"key":"11102_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"11102_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2018.0753","volume":"29","author":"ST Crooke","year":"2019","unstructured":"Crooke ST, Baker BF, Xia S, Yu RZ, Viney NJ, Wang Y, et al. Integrated assessment of the clinical performance of GalNAc(3)-conjugated 2\u2019-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience. Nucleic Acid Ther. 2019;29(1):16\u201332","journal-title":"Nucleic Acid Ther"},{"issue":"7","key":"11102_CR26","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s40121-024-00980-9","volume":"13","author":"AS Youssef","year":"2024","unstructured":"Youssef AS, Ismail M, Han K, Magee M, Nader A. Population pharmacokinetics of bepirovirsen in healthy participants and participants with chronic hepatitis B virus infection: results from phase 1, 2a, and 2b studies. Infect Dis Ther. 2024;13(7):1515\u20131530","journal-title":"Infect Dis Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11102-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:41:06Z","timestamp":1787758866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11102-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11102"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11102-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jinlin Hou is a consultant for and has received grant\/research support from Aligos, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Hepa Sera. Authors affiliated with Ausper Biopharma or AusperBio are employees of the sponsor. The remaining authors disclose no conflicts.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and consent forms were approved by the ethics committees at each participating site. All participants provided written informed consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}